ACC-SFBA Patent Law Committee Meeting Sponsored by Sheppard Mullin LLP
Overview
Protecting a company’s substantial investment in drug and biologic discovery is key to a product’s commercial success. Market exclusivity has the potential to drive innovation for large and small molecules, and also orphan drugs and other niche drugs with a limited market. In this session, we will explore strategies for maximizing exclusivity from both a patent and FDA regulatory perspective. We also will discuss the opportunities and challenges of attaining market exclusivity from in-house attorneys at both large and small molecule companies.
Panelists:
- Allison Fulton, Partner, Sheppard Mullin
- Lauren Stevens, Consultant, Global Patent Group, LLC
- Leslie Robbins, Senior VP Intellectual Property, CytomX Therapeutics
- Lorna Tanner, Partner, Sheppard Mullin
Schedule
4:30 p.m. - 5:00 p.m. Registration
5:00 p.m. - 6:00 p.m. Program
6:00 p.m. - 6:30 p.m. Networking
CLE
Credits: 1 Hour
State: CA
Category: General
Location
Sheppard Mullin
Four Embarcadero Center,
17th floor
San Francisco, CA 94111
Cost
Members: Free
Non-members: $50
Questions? Please contact Belinda Ashong via email or 415.774.3171